Paramita Therapeutics, Inc. is an early-stage biotech startup structured around development of water-soluble multivalent conjugation platform technologies. With the firm's mission defined as to eradicate cancer and infectious disease, the firm's principals have developed a new water-soluble multivalent platform and generated proof-of-concept data in mice. The firm's SBIR project is designed to build on that begining to develop multivalent peptide conjugates for a dual-function therapeutic and vaccine product of COVID-19. and continue with the R&D cancer drugs and dual-function therapeutic/vaccine product.
